Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5107 - Tolerability of PCV in Low Grade Glioma: a Real World Experience


28 Sep 2019


Poster Display session 1


Tumour Site

Central Nervous System Malignancies


Razia Aslam


Annals of Oncology (2019) 30 (suppl_5): v143-v158. 10.1093/annonc/mdz243


R. Aslam1, R. KEOGH2, M. Hennessy3, Z. Coyne3, B.T. Hennessy4, O.S. Breathnach5, L. Grogan6, P.G. Morris6

Author affiliations

  • 1 Medical Oncology, Beaumont Hospital, D08 NHY1 - Dublin/IE
  • 2 Medical Oncology, Beaumont Hospital, DUBLIN/IE
  • 3 Medical Oncology, Beaumont Hospital, Dublin/IE
  • 4 Medical Oncology, Beaumont Hospital Cancer Centre, D09 FT51 - Dublin/IE
  • 5 Medical Oncology, Beaumont Hospital, D09 FT51 - Dublin/IE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5107


In the phase III RTOG 9802 trial, median overall survival (OS) increased from 7.8 years with radiotherapy alone to 13.3 years (P = .002) with adjuvant procarbazine, lomustine, and vincristine (PCV) following surgery for low grade glioma. Although the PCV regimen improved survival, there were significant toxicities. We hypothesised more frequent toxicities would be observed in clinical practice. We aimed to identify and quantify toxicities in the real world setting in a National Neuro-Oncology centre.


Patients with low grade glioma who received PCV following radiotherapy from Nov 2014 to Nov 2018 were identified from Institutional databases. Data on toxicities, dose reductions, dose delays and treatment discontinuation were collected from paper and electronic patient records.


A total of 41 patients with low grade glioma were identified. Patients were predominantly male (n = 28) and the median age at diagnosis was 41. Of these, 28/41 patients had a diagnosis of oligodendroglioma and 13/41 had astrocytoma. The majority of patients had tumours with favourable molecular features such as IDH mutations (n = 38) and 1p19q co deletions (n = 23). Only 4 patients completed 6 cycles of chemotherapy without any dose modification or delay. 16 patients completed PCV with dose reductions and dose delays at various levels. The dose intensity was as follows: procarbazine: 69%, lomustine: 71% and vincristine: 68%. Neutropaenia and thrombocytopaenia (table) were the major causes of treatment discontinuation (14/21 patients). Three patients had disease progression during chemotherapy and two patient’s treatment was discontinued due to abnormal LFTs. Three patients opted not to continue chemo due to intolerability in context of grade 3 to 4 fatigue and GI symptoms. At median follow up of 17 months, 9/41 patients have had disease progression.Table: 430P

Our Study %RTOG 9802%
Patient Completed PCV4856
Median Number of Cycles Completed33.5
ThrombocytopeniaG2 (50-75)719
G3 (25-50)1718
G4 (<25)20


Frequent toxicities are observed with PCV in clinical practice. Our data suggest it might be preferable to adjust doses from the start of chemotherapy to improve tolerability.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.